ITEM 8.01 OTHER EVENTS

On October 27, 2009, Bayer HealthCare Pharmaceuticals Corporation, or Bayer, in its “Q3 2009 Analyst and Investor Briefing,” announced net sales of Nexavar for the quarter ending September 30, 2009 of €161 million. Quarterly Nexavar sales are translated into U.S. dollars based on an average exchange rate over the period. The approximate average exchange rate for the quarter ending September 30, 2009 was $1.43 for €1. Under the Collaboration Agreement between Bayer and Onyx, Bayer and Onyx share profits from global Nexavar sales, except in Japan where Onyx receives a single digit royalty on Nexavar net sales.

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.